Researchers reported multi‑omics and physiologic analyses from a pig‑to‑human kidney xenotransplant in a brain‑dead recipient, mapping immune responses over a 61‑day period and identifying antibody and T‑cell drivers of rejection. The team reversed rejection using existing FDA‑approved immunomodulatory drugs, demonstrating control of immune injury without permanent organ damage. The studies (published in Nature) profiled human and pig gene expression and immune cell dynamics in the graft, providing day‑by‑day snapshots of rejection biology. Investigators used that granular data to tailor combination therapies that tempered both humoral and cellular responses and restored graft function. The findings offer practical insights for clinical xenotransplant programs: (1) genetically engineered pig organs can functionally replace human kidneys, (2) detailed immune monitoring reveals actionable pathways, and (3) targeted drug combinations may manage rejection in future living recipients. The results accelerate plans for controlled clinical trials and highlight translational readiness in xenotransplantation.